Roger Vilardaga Viera to Mental Disorders
This is a "connection" page, showing publications Roger Vilardaga Viera has written about Mental Disorders.
Connection Strength
3.250
-
Browne J, Halverson TF, Vilardaga R. Engagement with a digital therapeutic for smoking cessation designed for persons with psychiatric illness fully mediates smoking outcomes in a pilot randomized controlled trial. Transl Behav Med. 2021 Sep 15; 11(9):1717-1725.
Score: 0.720
-
Vilardaga R, Rizo J, Palenski PE, Mannelli P, Oliver JA, Mcclernon FJ. Pilot Randomized Controlled Trial of a Novel Smoking Cessation App Designed for Individuals With Co-Occurring Tobacco Use Disorder and Serious Mental Illness. Nicotine Tob Res. 2020 Aug 24; 22(9):1533-1542.
Score: 0.669
-
Vilardaga R, Rizo J, Ries RK, Kientz JA, Ziedonis DM, Hernandez K, McClernon FJ. Formative, multimethod case studies of learn to quit, an acceptance and commitment therapy smoking cessation app designed for people with serious mental illness. Transl Behav Med. 2019 Nov 25; 9(6):1076-1086.
Score: 0.635
-
Villatte JL, Vilardaga R, Villatte M, Plumb Vilardaga JC, Atkins DC, Hayes SC. Acceptance and Commitment Therapy modules: Differential impact on treatment processes and outcomes. Behav Res Ther. 2016 Feb; 77:52-61.
Score: 0.483
-
Vilardaga R, Rizo J, Kientz JA, McDonell MG, Ries RK, Sobel K. User Experience Evaluation of a Smoking Cessation App in People With Serious Mental Illness. Nicotine Tob Res. 2016 May; 18(5):1032-8.
Score: 0.481
-
McDonell MG, Leickly E, McPherson S, Skalisky J, Srebnik D, Angelo F, Vilardaga R, Nepom JR, Roll JM, Ries RK. A Randomized Controlled Trial of Ethyl Glucuronide-Based Contingency Management for Outpatients With Co-Occurring Alcohol Use Disorders and Serious Mental Illness. Am J Psychiatry. 2017 Apr 01; 174(4):370-377.
Score: 0.131
-
McDonell M, McPherson S, Vilardaga R, Srebnik D, Angelo FN, Leickly E, Saxon AJ, Roll J, Ries R. Preliminary findings: Contingency management targeting psycho-stimulant use results in secondary decreases in smoking for severely mentally ill adults. Am J Addict. 2014; 23(4):407-10.
Score: 0.103
-
Leickly E, McDonell MG, Vilardaga R, Angelo FA, Lowe JM, McPherson S, Srebnik D, Roll JM, Ries RK. High levels of agreement between clinic-based ethyl glucuronide (EtG) immunoassays and laboratory-based mass spectrometry. Am J Drug Alcohol Abuse. 2015 May; 41(3):246-50.
Score: 0.029